Travere Q4 net product sales $39.9M, FILSPARI PSFs total 1,452 in 2023; sNDA filing imminent

Travere Therapeutics, Inc.

2023-FY EPS reported -$1.50 revenue$145,238,000

Net product sales of $39.9M in Q4 2023 ($127.5M FY); driven by FILSPARI launch ($14.7M Q4).
Q4 2023 net loss $90.2M ($1.18/sh); cash and equivalents $566.9M at Dec 31, 2023.
Received 459 new patient start forms for FILSPARI in Q4; total 1,452 PSFs since Feb 2023 approval.
Expects to submit sNDA for full U.S. approval of FILSPARI in IgAN in Q1 2024; CHMP opinion on EU CMA also Q1.
Pivotal Phase 3 HARMONY study of pegtibatinase in HCU enrolling; topline data expected in 2026.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Travere Therapeutics, Inc. reported financial results for the quarter and fiscal year ended December 31, 2023.

Period: the quarter and fiscal year ended December 31, 2023
Result: reported results

Exact text from the filing

On February 15, 2024, Travere Therapeutics, Inc. (the “Company”) issued a press release announcing, among other things, its financial results for the quarter and fiscal year ended December 31, 2023.

View on SEC.gov

59 earnings releases filed in the last 30 days. Browse all earnings releases →

Travere Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001438533-24-000003

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.